Investigating the Truth Behind Claims on Menopausal Hormone Therapy and Its Health Benefits
Recently, high-profile figures like Dr. Marty Makary and RFK Jr. have made bold claims asserting that hormone therapy used to treat menopause symptoms offers profound, long-term health benefits, including reductions in cardiovascular disease, dementia, and even life savings. They also suggest that the Black Box warnings from the FDA were misleading and that recent research indicates these treatments are much safer and more beneficial than traditionally understood. However, a careful review of the scientific literature indicates that these claims are misleading and lack support from the broader body of high-quality evidence.
First, Makary and Kennedy’s assertion that hormone therapy can cut the risk of cardiovascular disease by 50% is an oversimplification. The basis for this claim originates from older observational studies and post hoc subgroup analyses, such as one referenced from a 2015 Cochrane review, which highlights that the benefits are only observed under very specific conditions—namely, women who start therapy within 10 years of menopause and use transdermal formulations. Leading experts like Dr. Chrisandra Shufelt and Dr. Marcia Stefanick from the Mayo Clinic and Stanford University, respectively, emphasize that randomized controlled trials (RCTs), which are the gold standard in scientific research, do not confirm such large protective effects. Instead, they reveal that hormone therapy, when initiated later in postmenopause or used long-term, does not significantly decrease cardiovascular risks and may even increase them in certain populations.
- The Women’s Health Initiative (WHI), a landmark RCT, found that hormone therapy did not reduce and may have increased the risk of heart attack, stroke, and breast cancer over long-term follow-up, especially for women starting therapy many years after menopause.
- Meta-analyses and subsequent trials have consistently shown that hormone therapy’s potential cardiovascular benefits are only confirmed in specific subgroups—particularly younger women close to the onset of menopause—further emphasizing that blanket claims are distinct from the nuanced reality.
- Experts agree that while newer delivery methods like transdermal estrogen may pose fewer risks than older oral formulations, definitive evidence of cardiovascular protection is lacking.
Similarly, the claim that hormone therapy can significantly reduce the risk of dementia by 35% and cognitive decline by 64% is sourced from selective studies that have been criticized for overgeneralization. In reality, comprehensive reviews, including the 2022 position statement from the Menopause Society, conclude that high-quality evidence does not support using hormone therapy for cognitive protection across the board. Larger, more recent studies indicate no benefit in slowing or preventing dementia and suggest potential harm for women over age 70 who initiate therapy later in life.
Furthermore, claims that hormone therapy cuts the risk of breast cancer are also overstated. While the WHI study did find a statistically significant increase in breast cancer risk in women on combined estrogen-progestin therapy, it’s critical to note that some of these findings are complex. The same study demonstrated that estrogen-only therapy actually decreased breast cancer risk over the long term. Leading oncologists and researchers, including Dr. Nanette Santoro, point out that the evidence for increased breast cancer in hormone users is nuanced and depends heavily on the type, timing, and duration of therapy.
Importantly, authorities such as the American College of Obstetricians and Gynecologists endorse hormone therapy for menopausal symptoms when prescribed thoughtfully, taking individual risk factors into account. They emphasize that hormone therapy should not be viewed as a preventive measure for chronic diseases like cardiovascular disease or dementia and caution against oversimplified claims. As Dr. Rebecca Thurston notes, the current scientific consensus is clear: hormone therapy is an effective option for symptom relief, but its use for long-term disease prevention remains unsupported by the highest quality evidence.
Conclusion
The importance of accurate, evidence-based information cannot be overstated. While some research suggests potential benefits of hormone therapy in specific contexts, the claims of dramatic protections against cardiovascular disease and dementia, made by figures like Makary and Kennedy, are not substantiated by rigorous scientific consensus. Recognizing the limits of current evidence is essential for responsible citizenship and maintaining public trust in health decisions. As citizens and consumers, it’s our duty to rely on comprehensive, peer-reviewed science rather than cherry-picked studies or exaggerated narratives, thereby upholding the principles of transparency and rationality that underpin democracy.
